ASH 2021 | Tagraxofusp: from BPDCN to other myeloid malignancies
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the use of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other myeloid malignancies such as acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). Tagraxofusp is a CD123-targeted agent originally approved for patients with BPDCN. Early-stage trials have recently shown that this agent appears to be safe and effective in both MF (NCT02268253) and CMML (NCT02268253) in the relapsed/refractory (R/R) setting and suggest that it should be further evaluated in clinical trials as a single agent or in different combinations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
